

ondine



For Immediate Release

Periowave™ Gum Disease Therapy: Positive Results From Meta-analysis

Vancouver, Canada – September 10, 2007 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company, today announced results of a meta-analysis (statistical review of pooled clinical trial data) of its Periowave™ Photodynamic Disinfection System in the treatment of gum disease. The analysis covered three trials enrolling a total of 126 patients at four clinical centers over the past two years. Among other data, the meta-analysis found that Periowave™ used in a re-treatment protocol (six weeks apart) produced 2.3 times more clinically relevant (2+ mm) pocket depth reductions than the gold standard of scaling and root planing (SRP) alone ($p < 0.0001$).

Studies included a trial at an independent clinic in Everett, WA where clinically and statistically significant endpoints were achieved; a two-center study conducted by Loma Linda University where clinically and statistically significant endpoints were achieved and a study conducted by University of British Columbia where it was found that the protocol allowed for too few patients meeting inclusion criteria to be recruited. Patients who did meet inclusion criteria were included in the meta-analysis. No treatment-related adverse events were reported at any center. Endpoints included pocket depth, clinical attachment level and bleeding on probing.

The meta-analysis results supported prior findings, demonstrating that Periowave™ was safe and effective in producing statistically and clinically relevant improvements in periodontal pocket depth compared to scaling and root planing. Periowave™ produced more than double the number of large (2+ mm) pocket depth reductions than scaling and root planing alone ($p < 0.0001$). The results were achieved across studies that incorporated different ethnic groups, smoking status, treatment protocols and laser power levels.

“These positive meta-analysis results will be integrated into our FDA submission,” said Carolyn Cross, CEO and President of Ondine Biopharma. “Periowave™ has now been successfully tested in standard recall patients, patients with advanced disease, patients undergoing re-treatment protocols and patients with recurrent disease. In addition, Periowave™ has already been extensively deployed in the dental clinic following its approval in Canada and the European Union, with several thousand patients treated to date. Periowave™ has proven to be a safe and effective adjunct to SRP in many patients, irrespective of demographics, smoking status or nature of the disease”.

About Periowave™ and Photodisinfection

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated photosensitive compounds to specifically target and

destroy microbial pathogens and reduce the symptoms of disease. The compounds are topically applied and lasers of appropriate wavelength and intensity are used to disinfect the treatment site.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at:

www.ondinebiopharma.com

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

For further information please contact:

Carolyn Cross	Christina Bessant	Nominated Adviser
President and	Investor Relations	Neil Johnson /
Chief Executive Officer	The Equicom Group Inc.	Ryan Gaffney
Ondine Biopharma Corporation	(416) 815-0700 ext. 269	Canaccord Adams Ltd
(604) 669-0555	cbessant@equicomgroup.com	+44(0)20 7050 6500
ccross@ondinebiopharma.com		